Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: VIP152 (BAY 1251152)
DRUG: VIP152 (BAY 1251152) 30 mg
DRUG: Keytruda
DRUG: VIP152 (BAY 1251152) 15 mg

Sponsor

Vincerx Pharma, Inc.